BPOM and Ubaya Strengthen Research and Pharmaceutical Industry Collaboration
Surabaya (ANTARA) - The Indonesian Food and Drug Authority (BPOM) and the University of Surabaya (Ubaya) are strengthening research collaboration within the pharmaceutical industry through synergy between academia, business, and government to accelerate the downstreaming of innovation and the development of health products beneficial to the public.
“We are confident that technology transfer and the development of innovative products can be accelerated so that the benefits can be immediately felt by the community through the Academic, Business, and Government (ABG) concept,” said the Head of BPOM RI, Taruna Ikrar, during a public lecture and the signing of a memorandum of understanding at Ubaya on Monday.
Taruna stated that many research results from universities have the potential to meet public needs, particularly in the healthcare sector. These innovative products need to be encouraged to reach the public more quickly while still ensuring safety, quality, and efficacy.
“Some of these innovative products are essential for the community, including those related to various treatments, especially for diseases that have been difficult to cure,” he said.
He added that Indonesia possesses vast biodiversity potential that can be developed into medicinal raw materials. There are approximately 31,000 plant species with the potential to serve as sources for research-based pharmaceutical product development.
“We hope that research into this biodiversity potential continues to be conducted by universities so that it can produce products that are safe, high-quality, and beneficial to the public,” he said.
To accelerate the downstreaming of innovation, BPOM is preparing several regulatory breakthroughs. One of these is through a conditional approval scheme for innovative products that are urgently needed by the public.
According to Taruna, this policy allows products that have met safety aspects and demonstrated effectiveness at a certain stage to gain faster access to the public while continuing the collection of further clinical data.
Additionally, BPOM has reduced the product licensing evaluation time from approximately 300 working days to 210 working days. The government is also providing registration ease for micro and small enterprises, particularly for processed food products.
Taruna noted that there are currently around 1,700 research-based products in various stages of development in Indonesia. Of that number, approximately 134 products have shown significant progress, including therapies for cancer, critical illnesses, and several rare diseases.
“The most important thing is how these research results can reach the community while still guaranteeing safety, efficacy, and quality,” he said.
Meanwhile, the Rector of Ubaya, Dr Benny Lianto, stated that East Java still requires clinical trial facilities to support the development of new drugs. He noted that Ubaya has initiated the development of a clinical trial unit to support the needs of the pharmaceutical industry in East Java. The presence of such a facility is expected to complement the regional pharmaceutical industry ecosystem.
According to Benny, collaboration between BPOM, universities, and industry has the potential to strengthen the health research and innovation ecosystem in East Java.
Source: jawawa.id (https://jawawa.id/newsitem/bpom-and-ubaya-strengthen-research-and-pharmaceutical-industry-collaboration-1781520964)
Originally published by Antara (Indonesian) (https://www.antaranews.com/berita/5608973/bpom-dan-ubaya-perkuat-kolaborasi-riset-dan-industri-farmasi), translated from Indonesian